Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

477 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.
Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S; Heart Outcomes Prevention Evaluation (HOPE) Investigators. Mathew J, et al. Among authors: sleight p. Circulation. 2001 Oct 2;104(14):1615-21. doi: 10.1161/hc3901.096700. Circulation. 2001. PMID: 11581138 Clinical Trial.
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, et al. Among authors: sleight p. Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29. Lancet. 2008. PMID: 18757085 Clinical Trial.
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.
Copland E, Canoy D, Nazarzadeh M, Bidel Z, Ramakrishnan R, Woodward M, Chalmers J, Teo KK, Pepine CJ, Davis BR, Kjeldsen S, Sundström J, Rahimi K; Blood Pressure Lowering Treatment Trialists' Collaboration. Copland E, et al. Lancet Oncol. 2021 Apr;22(4):558-570. doi: 10.1016/S1470-2045(21)00033-4. Lancet Oncol. 2021. PMID: 33794209 Free PMC article.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Heart Outcomes Prevention Evaluation Study Investigators, et al. Among authors: sleight p. N Engl J Med. 2000 Jan 20;342(3):145-53. doi: 10.1056/NEJM200001203420301. N Engl J Med. 2000. PMID: 10639539 Free article. Clinical Trial.
Vitamin E supplementation and cardiovascular events in high-risk patients.
Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Heart Outcomes Prevention Evaluation Study Investigators, et al. Among authors: sleight p. N Engl J Med. 2000 Jan 20;342(3):154-60. doi: 10.1056/NEJM200001203420302. N Engl J Med. 2000. PMID: 10639540 Free article. Clinical Trial.
Blood-pressure reduction and cardiovascular risk in HOPE study.
Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J; Heart Outcomes Prevention Evaluation (HOPE) Study. Sleight P, et al. Lancet. 2001 Dec 22-29;358(9299):2130-1. doi: 10.1016/S0140-6736(01)07186-0. Lancet. 2001. PMID: 11784631
477 results